Clinical Metabolomics studies in diagnosing Prediabetes and Type 2 Diabetes: Unveiling Trends through Bibliometric Analysis

This bibliometric analysis of 1,742 studies published through May 2025 maps the global landscape of clinical metabolomics research on prediabetes and type 2 diabetes, identifying key contributors, leading journals, and emerging hotspots such as gut microbiota and lipidomics to guide future early diagnosis and precision interventions.

The Gist

Imagine your body is a massive, bustling city. For years, scientists have been trying to figure out why this city sometimes gets stuck in traffic jams (diabetes) long before the gridlock becomes impossible to fix.

This paper is like a giant map-making expedition. Instead of looking at individual cars (patients), the authors looked at the entire history of traffic reports (scientific papers) to see where the research is going, who is driving the most, and what new roads are being built.

Here is the breakdown of their journey, explained simply:

1. The Problem: The "Silent Fog"

The city of your body has a stage called Prediabetes. It's like a thick fog rolling in. You can't see the danger yet, and you feel fine, but the traffic lights are starting to malfunction.

• The Old Way: Doctors used to check the fog with a flashlight (blood sugar tests). But the flashlight is dim; it often misses the fog until it's too late.
• The New Way (Metabolomics): This is like installing satellite cameras that can see the tiny chemical changes in the air before the fog gets thick. It looks at the "exhaust fumes" (metabolites) your body produces to predict a traffic jam before it happens.

2. The Expedition: Counting the Maps

The authors didn't just read one or two papers; they gathered 1,742 scientific maps (studies) from around the world. They used special computer software (VOSviewer and CiteSpace) to act as their GPS, analyzing trends like a detective looking for clues.

Who is driving the most?

• China, the USA, and Germany are the top drivers. They have published the most maps.
• The Top Institutions: Harvard University and a German research center (Helmholtz) are like the biggest traffic control towers, producing the most influential research.
• The Top Authors: Two scientists, Jerzy Adamski (Germany) and Guowang Xu (China), are the "Master Navigators." They have written the most guides on how to read these chemical signals.

3. The Hotspots: What are they looking for?

The researchers found that the scientific community is currently obsessed with three main things, which they call "clusters":

• Cluster 1: The "Fuel Gauge" (Insulin Resistance): This is the core problem. The body's engine (cells) stops listening to the key (insulin). The researchers are trying to find the exact chemical "squeak" in the engine that tells us the key isn't working yet.
• Cluster 2: The "Trash Collectors" (Gut Microbiota): Your gut is full of tiny bacteria. Think of them as the city's sanitation crew. If they get out of balance, they start dumping toxic waste into the bloodstream, causing the traffic jam. The study shows that looking at what these bacteria are eating and pooping is a huge new trend.
• Cluster 3: The "Chemical Clues" (Lipids and Amino Acids):
  • Lipids (Fats): It's not just about "high cholesterol." It's about specific types of fat molecules acting like sticky tar on the roads.
  • Amino Acids (Proteins): Certain protein building blocks (like BCAAs) are like warning flares. If you see too many of them, it means the body is struggling to process food.

4. The Evolution: From Flashlights to AI

The paper describes how the research has changed over time, like upgrading a car:

• Phase 1 (The Early Days): Scientists were just building the flashlights. They were figuring out how to measure these chemicals accurately (using machines like Mass Spectrometry).
• Phase 2 (The Middle): They started connecting the dots. They realized that fats, proteins, and gut bacteria all talk to each other. It's not just one broken part; it's the whole engine system.
• Phase 3 (The Future): Now, they are building self-driving cars. They are combining all this data with Artificial Intelligence (AI) to create a "Crystal Ball." The goal is to look at your blood today and say, "In 5 years, you will get diabetes unless you change your diet."

5. The Big Takeaway

This study is a celebration of progress. It tells us that we are moving away from guessing and toward precision.

• The Old View: "You have high blood sugar; you have diabetes."
• The New View: "Your gut bacteria are producing too much of this specific chemical, your fat cells are leaking this specific toxin, and your insulin is struggling. Let's fix these specific things before you get sick."

In short: This paper is a roadmap showing that science is finally learning to read the body's "early warning system." By understanding the tiny chemical whispers of prediabetes, we can stop the traffic jam before it even starts, saving millions of people from the chaos of full-blown diabetes.

Technical Summary

1. Problem Statement

Type 2 Diabetes (T2D) and its precursor, Prediabetes (Pre-DM), represent a critical global public health challenge, with millions of undiagnosed cases due to the asymptomatic nature of the early stages.

• Diagnostic Limitations: Current clinical standards (OGTT, FPG, HbA1c) suffer from low sensitivity, time-consuming procedures, and high rates of missed diagnoses (e.g., FPG misses ~51.7% of Pre-DM cases).
• Research Gap: While metabolomics has shown promise in identifying early metabolic dysregulations and biomarkers, there is a lack of systematic, quantitative reviews that map the evolution, hotspots, and collaborative networks of clinical metabolomics research specifically focused on Pre-DM and T2D.
• Objective: The study aims to employ bibliometric analysis to visualize the developmental trajectory of this field, identify key research trends, and uncover emerging pathways for early diagnosis and precision intervention.

2. Methodology

The study utilized a rigorous bibliometric approach based on data from the Web of Science Core Collection (WOSCC).

• Data Collection:
  • Source: SCI-E and SSCI databases.
  • Timeframe: From database inception to May 23, 2025.
  • Search Strategy: Combined subject headings, free-text terms, and keywords related to metabolomics, prediabetes, and type 2 diabetes.
  • Filtering: Initial retrieval of 1,832 articles was refined by excluding non-article/review types, non-medical disciplines, duplicates, non-English papers, and irrelevant studies.
  • Final Dataset: 1,742 high-quality studies involving 13,505 researchers from 75 countries.
• Analytical Tools:
  • VOSviewer (v1.6.20): Used for probabilistic modeling-based normalization to generate collaboration networks, co-occurrence maps, and density visualizations.
  • CiteSpace (v6.2.R3): Used for set theory-based normalization to perform burst detection, identify research frontiers, and analyze temporal evolution.
• Metrics Analyzed: Publication volume, citation counts, country/institution/author collaboration networks, journal co-citation patterns, keyword co-occurrence, and burst detection.

3. Key Contributions

• First Comprehensive Bibliometric Map: This is the first study to quantitatively map the knowledge structure of clinical metabolomics specifically for Pre-DM and T2D, moving beyond general diabetes reviews.
• Evolutionary Trajectory Identification: The study delineates a distinct three-phase developmental path:
  1. Technology-Driven: Early focus on methodological advances (Mass Spectrometry, NMR).
  2. Mechanism Exploration: Shift toward specific pathways (Gut Microbiota, Lipidomics, Amino Acids).
  3. Clinical Integration: Current focus on precision prevention, specific complications (NASH, Diabetic Kidney Disease), and large-scale epidemiology.
• Identification of Core Intellectual Base: Pinpointed seminal works (e.g., Wang et al., 2011; Newgard et al., 2009) that established the predictive value of specific metabolites (BCAAs, aromatic amino acids) for diabetes onset.
• Collaboration Network Analysis: Mapped the global research landscape, highlighting the dominance of China and the US in output, and the critical role of specific institutions (Helmholtz Munich, Dalian Institute of Chemical Physics).

4. Key Results

A. Publication Trends and Geography

• Volume: Publications show a steady upward trend, exceeding 100 papers annually post-2018, with a significant peak in 2022.
• Geography: China leads in publication volume (32.84%), followed by the USA (26.81%) and Germany (9.82%). However, the USA leads in total citations, indicating higher impact per paper.
• Collaboration: Strong international ties exist, particularly between the US and China.

B. Research Hotspots and Clusters

Keyword co-occurrence analysis revealed five primary research clusters:

1. Technology & Biomarkers: Focus on validating metabolomic technologies for early warning.
2. Glucose Metabolism: Molecular mechanisms of gene expression and insulin regulation.
3. Obesity: Linking BMI and anthropometric indices to diabetes risk.
4. Insulin Resistance (IR) & Amino Acids: Specific focus on Branched-Chain Amino Acids (BCAAs) and acylcarnitines as drivers of IR.
5. Inflammation: The role of immune responses in metabolic dysregulation.

C. Emerging Frontiers (Burst Detection)

• Early Focus: Mass Spectrometry, Plasma, Metabonomics.
• Recent Trends (Last Decade): Gut Microbiota (highest burst intensity), Humans, Resistance, Metabolic Syndrome.
• Rising Topics: Diabetic Kidney Disease, Epidemiology, and host-microbiota co-metabolites (e.g., TMAO).

D. Key Biological Findings Summarized

The bibliometric analysis reinforced specific biological insights:

• Lipidomics: Abnormalities in phospholipids, free fatty acids (FFAs), and ceramides precede clinical diagnosis.
• Amino Acids: Elevated BCAAs and aromatic amino acids (AAAs) are robust predictors of Pre-DM (up to 10 years in advance), while Glycine shows an inverse correlation.
• Gut Microbiota: Dysbiosis leads to altered metabolites (TMAO, imidazole propionate) that impair insulin signaling, often appearing before clinical symptoms.

E. Leading Contributors

• Top Authors: Jerzy Adamski (Helmholtz Munich) and Guowang Xu (Dalian Institute of Chemical Physics) are the most prolific, driving research in biomarker discovery and methodological innovation.
• Top Institutions: Harvard University and Helmholtz Association lead in output; top journals include Metabolites, Scientific Reports, and Diabetes.

5. Significance and Future Directions

• Clinical Impact: The study validates that metabolomics offers a superior alternative to traditional screening by detecting subclinical metabolic shifts (e.g., lipid and amino acid disturbances) before hyperglycemia occurs.
• Strategic Shift: The field is transitioning from single-biomarker discovery to multi-omics network analysis (integrating metabolomics, genomics, and microbiome data).
• Future Outlook:
  • Development of AI-assisted predictive models for risk stratification.
  • Focus on personalized intervention strategies targeting specific metabolic pathways (e.g., microbiome modulation).
  • Need for robust, large-scale clinical validation of identified biomarkers to enable widespread screening and precision medicine for diabetes prevention.

In conclusion, this bibliometric analysis provides a roadmap for researchers and clinicians, confirming that metabolomics is evolving from a technical exploration into a clinically integrated tool essential for the early detection and management of the global diabetes epidemic.